Nonlinear Pharmacokinetics of 5-Methoxy-N,N-dimethyltryptamine in Mice

5-Methoxy-N,N,-dimethyltryptamine (5-MeO-DMT), an abused serotonergic indolealkylamine drug, was placed into Schedule I controlled substance status in the United States as of January 19, 2011. In previous studies, we have shown the impact of monoamine oxidase A and cytochrome P450 2D6 enzymes on 5-MeO-DMT metabolism and pharmacokinetics. The aim of this study was to investigate 5-MeO-DMT pharmacokinetic properties after intravenous or intraperitoneal administration of three different doses (2, 10, and 20 mg/kg) to CYP2D6-humanized (Tg-CYP2D6) and wild-type control mice. Systemic exposure [area under the curve (AUC)] to 5-MeO-DMT was increased nonproportionally with the increase in dose. The existence of nonlinearity in serum 5-MeO-DMT pharmacokinetics was clearly manifested by dose-normalized AUC values, which were approximately 1.5- to 2.0-fold (intravenous) and 1.8- to 2.7-fold (intraperitoneal) higher in wild-type or Tg-CYP2D6 mice dosed with 10 and 20 mg/kg 5-MeO-DMT, respectively, than those in mice treated with 2 mg/kg 5-MeO-DMT. Furthermore, a two-compartment model including first-order absorption, nonlinear (Michaelis-Menten) elimination, and CYP2D6-dependent linear elimination from the central compartment was developed to characterize the intravenous and intraperitoneal pharmacokinetic data for 5-MeO-DMT in wild-type and Tg-CYP2D6 mice. In addition, 5-MeO-DMT was readily detected in mouse brain after drug treatment, and brain 5-MeO-DMT concentrations were also increased nonproportionally with the increase of dose. The results establish a nonlinear pharmacokinetic property for 5-MeO-DMT in mice, suggesting that the risk of 5-MeO-DMT intoxication may be increased nonproportionally at higher doses.

[1]  J. C. Winter,et al.  Psychedelic 5-methoxy-N,N-dimethyltryptamine: metabolism, pharmacokinetics, drug interactions, and pharmacological actions. , 2010, Current drug metabolism.

[2]  A. Yu.  Indolealkylamines: Biotransformations and Potential Drug–Drug Interactions , 2008, The AAPS Journal.

[3]  D. Stoff,et al.  5-Methoxy-N,N-dimethyltryptamine: behavioral and toxicological effects in animals. , 1976, Biological psychiatry.

[4]  J. Idle,et al.  Screening for endogenous substrates reveals that CYP2D6 is a 5-methoxyindolethylamine O-demethylase. , 2003, Pharmacogenetics.

[5]  C. Marsden,et al.  MDMA: On the translation from rodent to human dosing , 2009, Psychopharmacology.

[6]  Y. Katsumata,et al.  Characterization of eight biogenic indoleamines as substrates for type A and type B monoamine oxidase. , 1981, Biochemical pharmacology.

[7]  J. C. Winter,et al.  The Paradox of 5-Methoxy-N,N-Dimethyltryptamine An Indoleamine Hallucinogen That Induces Stimulus Control Via 5-HT1A Receptors , 2000, Pharmacology Biochemistry and Behavior.

[8]  R. Glennon,et al.  Serotonin receptor binding affinities of tryptamine analogues. , 1979, Journal of medicinal chemistry.

[9]  J. Idle,et al.  The Relative Contribution of Monoamine Oxidase and Cytochrome P450 Isozymes to the Metabolic Deamination of the Trace Amine Tryptamine , 2003, Journal of Pharmacology and Experimental Therapeutics.

[10]  B. R. Sitaram,et al.  Urinary excretion of 5-methoxy-N,N-dimethyltryptamine, N,N-dimethyltryptamine and their N-oxides in the rat. , 1987, Biochemical pharmacology.

[11]  U. McCann,et al.  Non-linear Pharmacokinetics of MDMA ( “ Ecstasy ” ) and its Major Metabolites in Squirrel Monkeys at Plasma Concentrations of MDMA that Develop After Typical Psychoactive Doses , 2008 .

[12]  R. Strassman,et al.  Methodology for and the determination of the major constituents and metabolites of the Amazonian botanical medicine ayahuasca in human urine. , 2011, Biomedical chromatography : BMC.

[13]  Tim Morris,et al.  Physiological Parameters in Laboratory Animals and Humans , 1993, Pharmaceutical Research.

[14]  J. Callaway,et al.  A demand for clarity regarding a case report on the ingestion of 5-methoxy-N, N-dimethyltryptamine (5-MeO-DMT) in an Ayahuasca preparation. , 2006, Journal of analytical toxicology.

[15]  M. Geyer,et al.  The roles of 5-HT1A and 5-HT2 receptors in the effects of 5-MeO-DMT on locomotor activity and prepulse inhibition in rats , 2006, Psychopharmacology.

[16]  E. Boyer,et al.  Monoamine Oxidase Inhibitor Poisoning Resulting from Internet Misinformation on Illicit Substances , 2004, Journal of toxicology. Clinical toxicology.

[17]  S. Barker,et al.  Distribution of the hallucinogens N,N-dimethyltryptamine and 5-methoxy-N,N-dimethyltryptamine in rat brain following intraperitoneal injection: application of a new solid-phase extraction LC-APcI-MS-MS-isotope dilution method. , 2001, Journal of chromatography. B, Biomedical sciences and applications.

[18]  B. R. Sitaram,et al.  In vivo metabolism of 5-methoxy-N,N-dimethyltryptamine and N,N-dimethyltryptamine in the rat. , 1987, Biochemical pharmacology.

[19]  J. Idle,et al.  The CYP2D6 humanized mouse: effect of the human CYP2D6 transgene and HNF4alpha on the disposition of debrisoquine in the mouse. , 2001, Molecular pharmacology.

[20]  J. Ott.  Pharmepéna-Psychonautics: Human Intranasal, Sublingual and Oral Pharmacology of 5-Methoxy-N, N-Dimethyl-Tryptamine , 2001, Journal of psychoactive drugs.

[21]  L. Rhomberg,et al.  Use of quantitative modelling in methylene chloride risk assessment. , 1995, Toxicology.

[22]  A. Yu,et al.  Development of a LC-MS/MS method to analyze 5-methoxy-N,N-dimethyltryptamine and bufotenine, and application to pharmacokinetic study. , 2009, Bioanalysis.

[23]  M. Geyer,et al.  Modification of the effects of 5-methoxy-N,N-dimethyltryptamine on exploratory behavior in rats by monoamine oxidase inhibitors , 2008, Psychopharmacology.

[24]  A. Yu,et al.  Effects of monoamine oxidase inhibitor and cytochrome P450 2D6 status on 5-methoxy-N,N-dimethyltryptamine metabolism and pharmacokinetics. , 2010, Biochemical pharmacology.

[25]  J. Lindgren,et al.  Metabolism of 5-methoxy-N,-N dimethyltryptamine- 14 C in the rat. , 1969, Biochemical pharmacology.

[26]  M. Huestis,et al.  Effects of Dose and Route of Administration on Pharmacokinetics of (±)-3,4-Methylenedioxymethamphetamine in the Rat , 2009, Drug Metabolism and Disposition.

[27]  J. F. Alder,et al.  An analytical perspective on favoured synthetic routes to the psychoactive tryptamines. , 2004, Journal of pharmaceutical and biomedical analysis.

[28]  L. C. Clark,et al.  5-methoxy-N, N-dimethyltryptamine, a possible endogenous psychotoxin. , 1965, The Alabama journal of medical sciences.

[29]  R. Squires.  EVIDENCE THAT 5‐METHOXY‐N, N‐DIMETHYL TRYPTAMINE IS A SPECIFIC SUBSTRATE FOR MAO‐A IN THE RAT: IMPLICATIONS FOR THE INDOLEAMINE DEPENDENT BEHAVIOURAL SYNDROME , 1975, Journal of neurochemistry.

[30]  U. McCann,et al.  Nonlinear Pharmacokinetics of (±)3,4-Methylenedioxymethamphetamine (MDMA, “Ecstasy”) and Its Major Metabolites in Squirrel Monkeys at Plasma Concentrations of MDMA That Develop After Typical Psychoactive Doses , 2008, Journal of Pharmacology and Experimental Therapeutics.

[31]  D. Mckenna.  Clinical investigations of the therapeutic potential of ayahuasca: rationale and regulatory challenges. , 2004, Pharmacology & therapeutics.

[32]  B. Levine,et al.  A fatal intoxication following the ingestion of 5-methoxy-N,N-dimethyltryptamine in an ayahuasca preparation. , 2005, Journal of analytical toxicology.

[33]  M. Vila,et al.  Localization of monoamine oxidases in human peripheral tissues. , 1996, Life sciences.

[34]  B. R. Sitaram,et al.  Observations on the metabolism of the psychotomimetic indolealkylamines: Implications for future clinical studies , 1990, Biological Psychiatry.

[35]  R. Lledo-Garcia,et al.  A Pharmacokinetic Model for Evaluating the Impact of Hepatic and Intestinal First-Pass Loss of Saquinavir in the Rat , 2011, Drug Metabolism and Disposition.

[36]  R. de la Torre,et al.  Non-linear pharmacokinetics of MDMA ('ecstasy') in humans. , 2000, British journal of clinical pharmacology.

[37]  G. Tonn,et al.  An Inhibitory Metabolite Leads to Dose- and Time-Dependent Pharmacokinetics of (R)-N-{1-[3-(4-Ethoxy-phenyl)-4-oxo-3,4-dihydro-pyrido[2,3-d]pyrimidin-2-yl]-ethyl}-N-pyridin-3-yl-methyl-2-(4-trifluoromethoxy-phenyl)-acetamide (AMG 487) in Human Subjects After Multiple Dosing , 2009, Drug Metabolism and Disposition.

[38]  L. Kochersperger,et al.  Immunocytochemical localization of monoamine oxidases A and B in human peripheral tissues and brain. , 1987, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[39]  Ai-Ming Yu,et al.  Drug-metabolizing enzyme, transporter, and nuclear receptor genetically modified mouse models , 2011, Drug metabolism reviews.